Inovio Pharmaceuticals (INO) Raised to Hold at ValuEngine
ValuEngine upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a hold rating in a report published on Wednesday.
INO has been the topic of a number of other research reports. BidaskClub cut shares of Inovio Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, June 28th. Maxim Group set a $8.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, May 10th. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, May 16th. Finally, Zacks Investment Research raised shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, July 3rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $11.25.
Shares of NASDAQ:INO opened at $5.38 on Wednesday. Inovio Pharmaceuticals has a twelve month low of $3.64 and a twelve month high of $7.00. The company has a market capitalization of $485.85 million, a P/E ratio of -4.94 and a beta of 1.83.
In other news, CFO Peter Kies sold 35,000 shares of the stock in a transaction that occurred on Tuesday, July 10th. The stock was sold at an average price of $4.44, for a total transaction of $155,400.00. Following the transaction, the chief financial officer now owns 97,088 shares in the company, valued at approximately $431,070.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 9.40% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the company. Levin Capital Strategies L.P. lifted its position in shares of Inovio Pharmaceuticals by 80.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 16,500 shares in the last quarter. Emerald Advisers Inc. PA purchased a new position in Inovio Pharmaceuticals in the 2nd quarter valued at $228,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Inovio Pharmaceuticals by 50.2% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 101,225 shares of the biopharmaceutical company’s stock valued at $397,000 after purchasing an additional 33,825 shares in the last quarter. Bank of America Corp DE lifted its holdings in Inovio Pharmaceuticals by 36.6% in the 2nd quarter. Bank of America Corp DE now owns 114,660 shares of the biopharmaceutical company’s stock valued at $449,000 after purchasing an additional 30,740 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in Inovio Pharmaceuticals by 14.3% in the 1st quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock valued at $689,000 after purchasing an additional 18,300 shares in the last quarter. Hedge funds and other institutional investors own 31.53% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: What is a closed-end mutual fund (CEF)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.